Tislelizumab: 12 agencies, 2023–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NYE METODER (Norway) has been easier on tislelizumab than on its own caseload: it refused 0 of 9 decisive submissions here (0%), against a base rate of 37% across everything it has assessed.
The record spans 3.4 years, opening at PHARMAC (New Zealand) on 13 Feb 2023 and running to 2026.
HAS (France) changed its position: not recommended on 6 Nov 2024, recommended by 22 Oct 2025, after a resubmission.
No assessment is on file from SMC (Scotland) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for tislelizumab, 3 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 47 of 48 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for tislelizumab by the agencies that label one in English (AWMSG, NICE and PBAC).
3 of these 48 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess tislelizumab, on 13 Feb 2023; DMC (Denmark) did not open a file until 1 Jun 2026 — a wide spread of 3.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 20 of 47 dated records fall in 2025 alone.
11 of the 12 agencies here assessed tislelizumab more than once, G-BA (Germany) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
tislelizumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tislelizumab reads 23 recommended, 9 no benefit, 6 not recommended and 3 terminated, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 17 Jun 2026 | SECRETARIA DE ESTADO DE SANIDAD 26 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicaciones terapéuticas autorizadas: Cá… | not financed by the SNS · art. 92 d | source |
| HIRA (South Korea) | 4 Jun 2026 | 절제 불가능 , 국소 진행성 또는 전이성 식도편평세포암 환자에서의 1 차 치료로서 백금 기반 항암화학요법과의 병용요법 | extension of coverage appropriate (risk-share extension) | source |
| DMC (Denmark) | 1 Jun 2026 | Tevimbra, i kombination med etoposid og platinbaseret kemoterapi, er indiceret til førstelinjebehandling af voksne patie… | Anbefalet | source |
| G-BA (Germany) | 19 Mar 2026 | Tevimbra — benefit assessment §35a | added benefit: not proven | source |
| NYE METODER (Norway) | 15 Mar 2026 | I kombinasjon med platinabasert kjemoterapi som neoadjuvant behandling, etterfulgt av monoterapi som adjuvant behandling… | introduced | source |
43 further decisions for tislelizumab, across 12 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 40 further source documents.
Related molecules
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 48 decisions for tislelizumab from 12 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.